Toll-like Receptor 7 Is Required for Effective Adaptive Immune Responses that Prevent Persistent Virus Infection  by Walsh, Kevin B. et al.
Cell Host & Microbe
ArticleToll-like Receptor 7 Is Required
for Effective Adaptive Immune Responses
that Prevent Persistent Virus Infection
Kevin B. Walsh,1 John R. Teijaro,1 Elina I. Zuniga,2 Megan J. Welch,1 Daniel M. Fremgen,1 Shawn D. Blackburn,3
Karl F. von Tiehl,1 E. John Wherry,3 Richard A. Flavell,4 and Michael B.A. Oldstone1,*
1Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
2Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA
3Department of Microbiology and Institute for Immunology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
4Department of Immunobiology, Yale University, New Haven, CT 06519, USA
*Correspondence: mbaobo@scripps.edu
DOI 10.1016/j.chom.2012.04.016SUMMARY
TLR7 is an innate signaling receptor that recognizes
single-stranded viral RNA and is activated by viruses
that cause persistent infections. We show that TLR7
signaling dictates either clearance or establishment
of life-long chronic infection by lymphocytic chorio-
meningitis virus (LCMV) Cl 13 but does not affect
clearance of the acute LCMV Armstrong 53b strain.
TLR7/ mice infected with LCMV Cl 13 remained
viremic throughout life from defects in the adaptive
antiviral immune response—notably, diminished
T cell function, exacerbated T cell exhaustion,
decreased plasma cell maturation, and negligible
antiviral antibody production. Adoptive transfer of
TLR7+/+ LCMV immune memory cells that enhanced
clearance of persistent LCMV Cl 13 infection in
TLR7+/+ mice failed to purge LCMV Cl 13 infection in
TLR7/ mice, demonstrating that a TLR7-deficient
environment renders antiviral responses ineffective.
Therefore, methods that promote TLR7 signaling
are promising treatment strategies for chronic viral
infections.
INTRODUCTION
Chronic viral infections such as human immunodeficiency
virus, hepatitis B virus, and hepatitis C virus (HCV) result in
dysfunctional immune responses, including altered innate
immune responses, T cell exhaustion, and defective B cell
responses (Frebel et al., 2010; Liu et al., 2009; Oliviero et al.,
2011; Urbani et al., 2006). Understanding the mechanisms that
cause viral persistence should lead to optimally planned thera-
pies to overcome such infections. For example, the subversion
of host T and B cell immune responses through upregulation
of host negative immune regulators (NIRs) effectively exacer-
bated persistence and blockade of NIR signaling such as
IL-10, PD-1, TGF-b, and LAG-3 resurrected T cell function that
enhanced viral clearance and terminated the persistent infectionCell H(Barber et al., 2006; Blackburn et al., 2009; Brooks et al., 2006;
Tinoco et al., 2009).
Lymphocytic choriomeningitis virus (LCMV) is a negative-
strand virus containing two RNA segments (Buchmeier et al.,
2007). The LCMV strain Armstrong (Arm) 53b, when inoculated
into mice intravenously (i.v.), generates an acute infection. As a
result, a robust anti-LCMV-specific CD8+ T cell response was
developed within 7 days and terminated the infection (Brooks
et al., 2006). Instillation of LCMV Arm 53b into newborn mice
resulted in a lifelong persistent infection (Oldstone, 2002). Isola-
tion of LCMV virus clones from splenic lymphoid cells of such
persistently infected mice resulted in the generation and charac-
terization of LCMVCl 13, an LCMV variant that differs from LCMV
Arm 53b by three amino acid residues (Ahmed et al., 1984;
Bergthaler et al., 2010; Salvato et al., 1991; Sullivan et al.,
2011). Inoculation of LCMV Cl 13 (2 3 106 PFU i.v.) caused
a systemic persistent virus infection that lasted for >90 days
(Ahmed et al., 1984).
Host immune factors exist to inhibit the dissemination of
microbes, terminate infection, and reduce harm to infected
tissues. However, host constituents like NIRs, which normally
function to retard and suppress an exaggerated, tissue injurious,
antiviral immune response are also utilized by viruses for
their own strategies to establish and maintain persistence. In
addition, disruption of vital innate signaling molecules such as
interferon-a/b (IFN-a/b) receptor and the myeloid differentiation
primary response gene 88 (MyD88) caused nonpersistent strains
of LCMV to avoid elimination and persevere (Jung et al., 2008;
van den Broek et al., 1995). MyD88 is an adaptor molecule for
toll-like receptors (TLRs), a class of signaling molecules of the
innate immune system that recognize pathogen-associated
molecular patterns derived from microbes (Moresco et al.,
2011). These receptors form the first line of defense against
pathogens. MyD88-dependent TLRs are TLR1, TLR2, TLR5,
TLR6, TLR7, TLR8, and TLR9. Signaling through such receptors
stimulates the production of inflammatorymediators, type I IFNs,
and cytokines with potent antimicrobe activity (Moresco et al.,
2011). LCMV stimulates type I IFN production byMyD88-depen-
dent signaling pathways and reportedly involves TLR2, TLR7,
and TLR9 (Borrow et al., 2010). The contribution of individual
TLRs that require MyD88 for signaling to control and eliminate
LCMV infection is unclear.ost & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevier Inc. 643
Figure 1. TLR7–/– Mice Eliminated an Acute LCMV Arm Infection, but
Failed to Terminate a Persistent LCMV Cl 13 Infection
TLR7+/+ (black circles) or TLR7/ (shaded circles) mice were infected with
2 3 106 PFU LCMV Arm or LCMV Cl 13 i.v.
(A) Virus burden in the liver of LCMV Arm and Cl 13 infected mice at the
specified time points. Circles represent individual mice, and the bars indicate
the average.
(B) LCMV Cl 13 titers were assayed in sera at specified time points.
Four to ten mice per group were used per time point, and data represent the
average ± SEM. *p < 0.05; **p < 0.005; ***p < 0.0005. See also Figure S1.
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TLR7 Deficiency and Lifelong Viral PersistenceTLR7was first identified as a receptor for single-stranded RNA
from vesicular stomatitis and influenza viruses as well as the
chemical ligands imiquimod and R-848 (Hemmi et al., 2002;
Lund et al., 2004). TLR7 is primarily expressed by plasmacytoid
dendritic cells (DCs), but also emanates from other DC subsets
and myelomonocytic cells, T cells, and B cells (Hammond
et al., 2010; Hemmi et al., 2002; Hornung et al., 2002; Kadowaki
et al., 2001). Signaling through TLR7 results in translocation
of IFN regulatory factor 7 (IRF7) and nuclear factor-kappaB
(NF-kB) to the nucleus, where IRF7 stimulates expression of
type I IFN, as well as IFN-inducible genes, and NF-kB elicits
production of inflammatory cytokines. TLR7 stimulates inflam-
matory responses in DCs and macrophages, enhances cytolytic
activity in CD8+ T cells and augments B cell class switching
(Ambach et al., 2004; Edwards et al., 2003; Heer et al., 2007;
Hemmi et al., 2002). Mice deficient in TLR7 are more susceptible
tomurine cytomegalovirus,West Nile virus (WNV), influenza virus
and Friend virus infections (Browne, 2011; Koyama et al., 2007;
Town et al., 2009; Zucchini et al., 2008).
Given the importance of TLR7 in recognition of viruses and
stimulation of multiple arms of the immune system, we investi-
gated the role of TLR7 during LCMV Cl 13 infection of mice,
the prototypic model for analyzing persistent virus infection.
Here we demonstrate that TLR7 sufficiency is essential for spon-
taneous termination of LCMV Cl 13 infection; in contrast, TLR7
deficiency resulted in lifelong persistence of this virus. The
mechanism for TLR7 deficiency leading to lifelong persistent644 Cell Host & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevierviral infection is dysfunction in T and B cell antiviral immune
responses, as well as exacerbated T cell exhaustion. Introduc-
tion of TLR7+/+ LCMV immune memory, despite enhancing viral
clearance in TLR7+/+ mice, failed to clear LCMV Cl 13 infection
in TLR7/ mice.
RESULTS
TLR7–/– Mice Purged LCMV Armstrong Infection, but Not
LCMV Cl 13, Resulting in Lifelong Persistence
TLR7+/+ and TLR7/ mice infected with LCMV Arm developed
an acute infection that was eliminated from the serum (data not
shown), liver (Figure 1A), brain (Figure S1A available online),
and kidney (Figure S1B) by day 9 postinfection (p.i.). To the
contrary, TLR7+/+ and TLR7/ inoculated with LCMV Cl 13
acquired a persistent viral infection that was detectable in the
liver (Figure 1A) and serum (Figure 1B) past days 70 and 60,
respectively. Although most organs of TLR7+/+ mice were nega-
tive for infectious LCMV Cl 13 progeny according to plaque
assays on day 100 p.i., in contrast, LCMV Cl 13 persisted in
the brain and kidneys for up to 200 days and 2–3 years, respec-
tively (Oldstone, 2002). TLR7+/+ mice infected with LCMV Cl 13
harbored replicating virus in the brain (Figure S1A) and kidney
(Figure S1B) at day 131 p.i.; however, the viral levels in TLR7+/+
declined between days 35 and 131 p.i., demonstrating that the
hosts’ immune response was clearing virus from these organs.
TLR7/ mice infected with LCMV Cl 13 retained high levels of
virus in their sera at all time points assayed (Figure 1B), and these
levels remained elevated throughout their lives (>day 320 p.i.).
The liver (Figure 1A), brain (Figure S1A) and kidney (Figure S1B)
of LCMV Cl 13-infected TLR7/ mice maintained >106 PFU/g
tissue throughout the course of infection. This viral burden was
significantly greater than that of virus levels in all tissues from
TLR7+/+ mice at days 70 and 131 p.i.
Lifelong virus persistence observed in TLR7/ mice was not
caused by disrupted early control of LCMV Cl 13 replication,
given that virus titer in the spleen, liver, lung, and kidney on
day 3 p.i. were not significantly different when evaluated against
TLR7+/+ mice (Figure S1C). Even though tissue virus burden was
unaltered, reductions in IFN-a (Figure S1D), IFN-b (Figure S1E),
CCL2, and CXCL10 (Figure S1F) were detected in LCMV Cl
13-infected TLR7/ mice. However, the levels of these cyto-
kines became equivalent to TLR7+/+ mice by day 2 p.i. (Fig-
ure S1G). Although, the levels of some cytokines were reduced
early in LCMV Cl 13-infected TLR7/ mice, they did not
adversely affect early control of LCMV replication. These results
demonstrate a biased requirement for TLR7 in controlling
chronic LCMV Cl 13 infection.
Diminished Antiviral T Cell Function and Exacerbated
Exhaustion in TLR7–/– Mice
Since T cells are essential for LCMV clearance, and functional
exhaustion of T cells correlates with viral persistence (Berger
et al., 2000; Zajac et al., 1998), we next investigated these factors
in TLR7+/+ and TLR7/ mice. The spleen of TLR7/ mice had
significantly more LCMV-specific CD8+ T cells (GP33-41, H-2D
b;
Figure 2A) and CD4+ T cells (GP66-77, I-A
b; Figure 2B) than those
of TLR7+/+mice on days 7 and 15 p.i. with LCMVCl 13. By day 35
p.i. and thereafter, both strains had equivalent numbers ofInc.
Figure 2. T Cells From TLR7–/– Mice Have Diminished Antiviral Functionality that Is Caused by T Cell Extrinsic Factors
TLR7+/+ and TLR7/ mice were infected with 2x106 PFU of LCMV Arm or Cl 13 i.v.
(A and B) Quantification of LCMV-specific CD8+ (LCMVGP33-41-specific) (A) and CD4
+ (LCMVGP67-77-specific) (B) T cells in the spleen by tetramer staining at the
specified time points.
(C) GP33-41 peptide stimulation of TLR7
+/+ and TLR7/ splenocytes harvested on day 9 p.i. with LCMV Arm or Cl 13. The left panel displays representative dot
plots of CD8+ IFN-g+ cells producing TNF-a and IL-2 with respective frequencies. The right panel exhibits the average frequencies of CD8+ IFN-g-only producers,
IFN-g-TNF-a dual producers, and IFN-g-TNF-a-IL-2 triple producers from LCMV Arm and Cl 13-infected mice.
(D) Frequencies of intracellular granzyme B+ GP33-41 tetramer
+ CD8+ T cells in the spleens of LCMV Cl 13-infected TLR7+/+ and TLR7/ mice.
(E) Quantification of adoptively transferred TLR7+/+ Thy1.1+ TCR tg CD8+ T cells (P14) in the spleens of Thy1.2+ TLR7+/+ and TLR7/mice on day 9 p.i. with LCMV
Arm or Cl 13 i.v.
(F and G) Frequencies of cytokine-producing LCMV GP61-80 or GP33-41 peptide-stimulated TLR7
+/+ Ly5.1+ TCR tg CD4+ (SMARTA) (F) and Thy1.1+ TCR tg CD8+
(P14) T cells (G), respectively, in the spleens of Thy1.2+ Ly5.2+ TLR7+/+ and TLR7/ mice 8 days after infection with LCMV Cl 13 i.v.
Bar graphs represent the average ± the SEM. Four to five mice per group were used. *p < 0.05; **p < 0.005; ***p < 0.0005. See also Figure S2.
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TLR7 Deficiency and Lifelong Viral PersistenceLCMV-specific CD8+ (Figure 2A) and CD4+ (Figure 2B) T cells in
the spleen. Elevated numbers of LCMV-specific CD8+ T cells
within the spleens of TLR7/ mice was not caused by a failure
to exit lymphoid tissue and/or enter infected peripheral tissue
since the numbers of such cells within the spleen (Figure S2A),
liver (Figure S2B), and brain (Figure S2C) of TLR7/ mice were
at levels either equal to or greater than the content found in
TLR7+/+ mice. Thus, TLR7/ mice displayed normal T cell
homing to infected tissues.
Since the TLR7/ host response against LCMVCl 13 resulted
in enhanced T cell expansion, but failure in viral clearance, life-
long persistence may be caused by disrupted antiviral T cell
function. To evaluate this point, we characterized T cell antiviral
polyfunctionality by analyzing cytokine and granzyme B produc-
tion by LCMV-specific T cells. To accomplish this, we cultured
splenocytes from TLR7+/+ and TLR7/ mice ex vivo with
peptides for the CD8+ and CD4+ T cell immunodominant LCMV
epitopes GP33-41 and GP61-80, respectively. GP33-41 peptide
stimulation of CD8+ T cells from TLR7/ mice infected with
LCMV Arm and Cl 13 had decreased frequencies of TNF-alpha
and IL-2 expressing cells in IFN-g+-gated cells compared
to identically stimulated CD8+ T cells from TLR7+/+ mice (Fig-
ure 2C, left panel). A significantly greater percentage of IFN-g-
only-producing and a significant reduction in frequencies of
multifunctional cytokine-producing CD8+ T cells, i.e., fewer
IFN-g, TNF-a dual producers (LCMV Arm only) and IFN-g,
TNF-a, IL-2 triple producers, were detected in TLR7/ mice
when compared to TLR7+/+ mice on day 9 p.i. (Figure 2C, right
panel). Ex vivo analysis of TLR7/ mice found significantly
diminished frequencies of granzyme B+ GP33-41 tetramer-
positive CD8+ T cells on days 15 and 35 p.i. when judged against
TLR7+/+ mice (Figure 2D). Granzyme B LCMV-specific CD8+
T cell frequencies in TLR7+/+ mice became equivalent to and
significantly less than in TLR7/ mice on days 70 and 131 p.i.,
time points at which viremia was spontaneously terminated in
TLR7+/+ mice. Although elevated numbers of virus-specific
T cells were observed in TLR7/ mice, these cells produced
lesser amounts of cytokines and granzyme B, thereby exhibiting
diminished antiviral potential.
Next we determined whether TLR7 deletion within T cells or
extrinsic factors caused by a TLR7-deficient environment
enhanced T cell proliferation and reduced antiviral cytokine
production. For that purpose, TLR7+/+ T cell receptor (TCR)
transgenic (Tg) CD8+ (P14, LCMV GP33-41-specific, H-2D
b) and
CD4+ (SMARTA, LCMV GP66-77-specific, I-A
b) T cells were
adoptively transferred into TLR7+/+ and TLR7/mice 1 day prior
to infection with LCMV Arm or Cl 13. These TLR7+/+ TCR Tg
CD8+ and CD4+ T cells expressed the congenic markers
Thy1.1 and Ly5.1, respectively, which assured the cells’ identifi-
cation when adoptively transferred into Thy1.2+ Ly5.2+ TLR7+/+
and TLR7/ mice. A significantly greater number of TCR Tg
Thy1.1+ CD8+ T cells were retrieved from the spleens of TLR7/
mice infected with either LCMV Arm or Cl 13 when compared to
TLR7+/+ mice on day 9 p.i. (Figure 2E). Additionally, GP61-80 (Fig-
ure 2F) and GP33-41 (Figure 2G) peptide stimulation of total sple-
nocytes significantly increased the frequencies of IFN-g-only
producing, as well as significantly reduced frequencies of
multiple antiviral cytokine producing endogenous and exoge-
nously administered TLR7+/+ TCR Tg T cells from TLR7/646 Cell Host & Microbe 11, 643–653, June 14, 2012 ª2012 Elseviermice when compared to TLR7+/+ mice 8 days after LCMV Cl
13 infection. Therefore, the enhanced expansion and diminished
polyfunctionality of LCMV-specific T cells observed within
TLR7/ mice were caused by environmental factors, not an
intrinsic property of T cells.
The cause of defective antiviral T cell responses may be
inherent to TLR7 deficiency in DCs, cells that preferentially
express and respond to TLR7 signaling. To evaluate this possi-
bility, DC subsets were analyzed for expression of functional
markers, virus antigen, and the ability to induce proliferation at
various time points after infection with LCMV Cl 13. Increased
and decreased expression of markers analyzed were noted in
plasmacytoid DCs (pDCs; Figure S2D), myeloid-derived DCs
(mDCs; Figure S2E) and CD8a+ DCs (Figure S2F). In addition,
significantly greater frequencies of LCMV Cl 13-infected
CD8a+ DCs (Figure S2G) and mDCs (Figure S2H) were detected
in TLR7/ mice at several different time points. DCs from the
spleens of TLR7+/+ and TLR7/ mice on day 35 p.i. induced
proliferation of TLR7+/+ TCR Tg CD8+ (P14) and CD4+ (SMARTA)
T cells equivalently (Figure S2I). In addition, DCs from TLR7/
mice on day 317 p.i. induced proliferation of TLR7+/+ TCR Tg
CD8+ T cells (P14) with or without the addition of LCMV GP33-41
peptide (Figure S2J). In vivo instillation of TLR7+/+ TCR Tg
CD8+ T cells (P14) into TLR7/ mice on day 85 p.i. resulted in
CD8+ T cell proliferation (Figure S2K). This proliferation was
compared to TLR7+/+ mice that had cleared LCMV Cl
13 systemic infection, but received 1 3 105 PFU LCMV Arm
1 day after TCR Tg CD8+ T cell (P14) transfer to stimulate cell
proliferation; however, the proliferative response was poor and
well below the expansion observed in TLR7/mice (Figure S2K).
Despite elevated infection and altered expression of activation
markers on TLR7/ DCs, DCs retained the ability to stimulate
T cell proliferation in vitro and in vivo.
Reduced antiviral functionality of CD8+ T cells from TLR7/
mice may have resulted from the cells’ exacerbated and/or
extended functional exhaustion. To address this issue, markers
of functional exhaustion were evaluated in TLR7+/+ and TLR7/
mice infected with LCMVCl 13. Accordingly, we determined that
programmed death-1 (PD-1) on LCMV-specific CD8+ T cells in
TLR7+/+ mice peaked on day 15 p.i., then dissipated over the
course of infection (Figure 3A). Compared to TLR7+/+ mice,
TLR7/ mice expressed significantly greater levels of PD-1 on
LCMV-specific CD8+ T cells on days 35, 70, and 131 p.i. (Fig-
ure 3A). Additional analysis of several NIR molecules on
LCMV-specific CD8+ T cells from TLR7/ mice 225 days after
LCMV Cl 13 infection revealed high levels of PD-1, LAG-3,
2B4, and CD160 (Figure 3B). This expression was greater than
that observed in a TLR7+/+ mouse at the same time point when
their systemic LCMV Cl 13 was purged. Clearly, TLR7/ mice
infected with LCMV Cl 13 lacked antiviral functionality and
suffered from immune system exhaustion, both of which indicate
a severely defective T cell compartment.
A TLR7 Deficiency Hampers the Anti-LCMV Antibody
Response
The TLR7 deficiency markedly impeded humoral immunity
when evaluated during influenza and Epstein-Barr virus
infections (Heer et al., 2007; Iskra et al., 2010). We there-
fore analyzed possible effects on the B cell response duringInc.
Figure 3. LCMV-Specific CD8+ T Cells from TLR7–/– Mice Have Enhanced Expression of NIRs
TLR7+/+ and TLR7/ mice were infected with 2 3 106 PFU LCMV Cl 13 i.v.
(A) Normalized PD-1 expression on the surface of GP33-41 tetramer
+ CD8+ T cells. Normalization of expression was performed by division the MFI of PD-1 on
GP33-41 tetramer
+ CD8+ T cells by the MFI of PD-1 on the PD-1 CD8+ T cell population. Data represent three to five mice per group from three separate
experiments. Bar graphs represent the average ± SEM. *p < 0.05; ***p < 0.0005.
(B) Expression of the NIRs on CD44+ GP33-41 tetramer
+ CD8+ T cells from the spleens of TLR7+/+ and TLR7/mice at day 225 p.i. Histogram data generated from
a single TLR7+/+ mouse that had cleared LCMV-Cl 13 systemically and a representative TLR7/mouse from a group of three that were viremic. MFI of specific
NIR is displayed on the top right of the panels for each individual mouse.
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TLR7 Deficiency and Lifelong Viral Persistencechronic LCMV Cl 13 infection. The generation of CD138+
plasma (Figure 4A) and IgM-secreting B cells (Figure 4B) in
spleens of TLR7/ mice was significantly reduced compared
to that of TLR7+/+ mice on day 20 p.i., the time point that
germinal center B cells were detected in TLR7+/+ mice. In addi-
tion, TLR7/ mice had a significantly decreased frequency of
germinal center B cells on days 20 and 35 p.i. (Figure 4C).
The absence of LCMV Cl 13 in TLR7+/+ mice yielded waning
frequencies of germinal center B cells on days 70 and 165
p.i., whereas germinal center formation increased in TLR7/
mice on day 165 p.i. In addition, ELISpot analysis revealed
significantly lower numbers of IgG secreting LCMV-specific B
cells in TLR7/ mice compared to the content in TLR7+/+
mice on day 33 p.i. (Figure 4D). Diminished germinal center B
cell formation, a reduction of plasma cells and fewer B cells
secreting LCMV-specific IgG correlated directly with a signifi-
cant decrease in LCMV-specific antibodies on days 35 (Fig-
ure 4E) and 74 (Figure 4F) p.i., demonstrating severely impeded
B cell antibody production in LCMV Cl 13 infected TLR7/
mice. Peptide-pulsed B cells from TLR7/ mice on day 35
p.i. induced TCR tg CD4+ (Figure S3A) and CD8+ (Figure S3B)
T cell proliferation equivalently to that observed in TLR7+/+
mice. Therefore, TLR7/ B cells maintained the ability to
stimulate T cell proliferation, but are defective in anti-LCMV
antibody production.Cell HTo determine whether this defect in the humoral immune
response in TLR7/ mice was caused by TLR7 deletion within
B cells, bone marrow chimeras were generated. Lethally irradi-
ated mice were reconstituted with a 1:1 mixture of cells from
Ly5.1+ TLR7+/+ mice and Ly5.2+ TLR7/ mice and infected
with LCMV Cl 13 2 months after reconstitution. The frequency
of TLR7/ splenic germinal center B cells was reduced signifi-
cantly below that of Ly5.1+ TLR7+/+ cells on day 30 after infec-
tion, effectively demonstrating that this defect in germinal center
B cell formation stemmed from their intrinsic TLR7 deficiency
(Figure 4G). Additionally, far fewer Ly5.2+ TLR7/ B cells
produced LCMV-specific IgG antibody compared to Ly5.1+
TLR7+/+ B cells harvested from the same mice, and resembled
that observed in TLR7/ mice that were neither irradiated nor
reconstituted (Figure 4H). Therefore, B cells required TLR7
signaling for germinal center reactions, conversion to plasma
cells, and production of LCMV-specific IgG antibody during
persistent LCMV Cl 13 infection.
Adoptive Transfer of TLR7+/+ Memory Cells into
Persistently Infected TLR7–/– Mice Failed to Purge
Infection
TLR7/ mice have negligible LCMV-specific antibody re-
sponse, diminished antiviral T cell function, and extended as
well as heightened T cell exhaustion after LCMV Cl 13 infection.ost & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevier Inc. 647
Figure 4. B Cell Intrinsic Defects in Plasma Cell Formation and the Generation of LCMV-Specific Antibody in TLR7–/– Mice
(A and B) TLR7+/+ and TLR7/mice were infected with 23 106 PFU LCMV Cl 13. The frequencies of CD138+- (A) and IgM-producing (B) splenic plasma cells on
day 20 p.i. are shown. The left panels are representative dot plots and the right panels are calculated averages ± SEM.
(C) The frequencies of splenic germinal center B cells (GL-7+ and CD38 based on the B220+, CD19+, IgD parent population) were determined at specified time
points.
(D–F) Quantification of the number of LCMV-specific IgG-secreting B cells from the spleens of TLR7/ and TLR7+/+ mice by ELISpot on day 33 p.i. (D). Serum
from LCMV Cl 13-infected TLR7/ and TLR7+/+ mice was harvested at days 35 (E) and 74 (F) p.i. and evaluated by ELISA to calculate the titer of anti-LCMV
specific antibody.
(G) Frequencies of TLR7+/+ (Ly5.1+ C57Bl/6) and TLR7/ (Ly5.2+ TLR7/) germinal center B cell formation in the spleens of bone marrow chimeric mice. The
left panel depicts representative histograms; the right panel is the calculated average ± SEM for frequencies.
(H) Enumeration by ELISpot of anti-LCMV antibody producing TLR7+/+ (Ly5.1+) and TLR7/ (Ly5.2+) B cells (CD19+, B220+) purified by FACS from bone-marrow
chimeras.
Bar graphs in (A)–(H) represent the average ± SEM. Each group contained four to fivemice and data are representative of two independent experiments. *p < 0.05;
**p < 0.005; ***p < 0.0005. See also Figure S3.
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memory cells as a means of augmenting their ability to purge
persistent LCMV Cl 13 infection. Because TLR7/ mice dis-
played an intrinsic B cell defect, immune memory splenic B cells
from TLR7+/+ mice were administered to TLR7+/+ or TLR7/
mice on day 15 p.i. with LCMV Cl 13. Subsequently, TLR7+/+
mice that received TLR7+/+ immune memory B cells terminated
infection earlier than TLR7+/+ mice that did not receive B cells,
demonstrating that these cells enhanced LCMV Cl 13 clearance
(Figure 5A). In contrast, TLR7/ mice that received TLR7+/+
immune memory B cells sustained viremia for the duration of
the experiment that was significantly greater (p < 0.0009,
day 42 posttransfer) than TLR7+/+ mice that did not receive648 Cell Host & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevierimmune memory B cells. Since other cell types may be required
for the elimination of LCMV Cl 13 infection, the experiment was
repeated with adoptive transfer of TLR7+/+ or TLR7/ total
immune memory splenocytes into TLR7+/+ or TLR7/ mice
15 days after infection with LCMV Cl 13. Viremia was terminated
in TLR7+/+ mice that received TLR7+/+ immune memory cells by
day 30 posttransfer (solid black circles, Figure 5B). In contrast,
TLR7+/+ mice that received TLR7/ immune memory (shaded
circle in Figure 5B) cleared LCMV Cl 13 by 68 days after transfer;
therefore, these mice did not reduce viral burden as efficiently as
TLR7+/+ recipients of TLR7+/+ LCMV immune memory cells (Fig-
ure 5B). Consequently, TLR7/ immune memory cells cleared
virus in vivo, but are less efficient in reducing viral load thanInc.
Figure 5. Adoptive Transfer of TLR7+/+
Memory Cells Fails to Clear LCMV Cl 13
Infection from TLR7–/– Mice
TLR7+/+ and TLR7/ mice were infected i.v. with
2 3 106 PFU LCMV Cl 13.
(A) Purified TLR7+/+ immune memory splenic
B cells (2 3 107) were adoptively transferred i.p.
into TLR7+/+ and TLR7/ mice on day 15 p.i.
Serum virus burden was calculated at specified
time points. The ratios listed in the right side of the
figure represent the number of nonviremic mice/
viremic mice.
(B and C) Total immune memory splenocytes (3 3
107) from TLR7+/+ or TLR7/ mice were adop-
tively transferred as mentioned above.
(B) Kinetic analysis of virus titer in the serum.
(C) Analysis of virus burden in sera and tissues of
recipient mice 73 days posttransfer. Symbols
represent individual mice, and black bars signify
mean values.
(A and B) TLR7+/+ mice that did not receive cells
(black diamonds) were used as controls for normal
LCMV Cl 13 clearance.
Data points represent the average ± the standard
error of the mean. Three to ten mice were used per
group per time point. Data are representative of
two to four independent experiments. See also
Figure S4.
Cell Host & Microbe
TLR7 Deficiency and Lifelong Viral Persistenceimmune memory cells generated in TLR7+/+ mice (Figure 5B),
correlating with the deficient functional T cell capacity of
TLR7/ mice infected with LCMV Arm (Figure 2C). In contrast,
unmanipulated TLR7/ mice (solid black diamonds) and
TLR7/ mice that received total TLR7+/+ or TLR7/ immune
memory splenocytes (designated by black and gray asterisks,
respectively) maintained viremia and showed no evidence
of clearing LCMV Cl 13 infection (Figure 5B). By day 73 post-
transfer, no virus was detectable in the serum, spleen, or liver
of TLR7+/+ mice that received either TLR7+/+ or TLR7/ immune
memory cells. In the brain and kidney of these mice, virus
was still detectable, but at lower levels than TLR7/ mice
persistently infected with LCMV Cl 13 from the same time point
(Figure 5C). In contrast, persistently infected TLR7/ mice
that received TLR7+/+ or TLR7/ immune memory cells
sustained high levels of virus in their sera and all tissues, indi-
cating that the adoptively transferred immune memory cells
failed to purge the infection (Figure 5C). Adoptively transferred
Ly5.2+ TLR7/ cells were clearly evident in the sera of Ly5.1+
TLR7+/+ recipients on day 45 posttransfer, indicating that theseCell Host & Microbe 11, 643–6cells had not been eliminated and
failure of clearance was not due to histo-
incompatability (Figure S4). Although the
adoptively transferred LCMV immune
memory cells enhanced viral clearance
in TLR7+/+ mice, these same cells failed
to eliminate viremia in TLR7/ mice.
Consequently, our overall results high-
light the importance of TLR7 signaling in
eliminating chronic viral infection. More-
over, the numerous immune defects in
TLR7/ mice, both cell intrinsic and
environmental, prevented viral clearance even after adoptive
immunotherapy.
DISCUSSION
The signaling receptor TLR7 is critical for the efficient control of
acute and persistent virus infections. Here we describe defects
of the antiviral immune response associated with the absence
of TLR7 during a persistent virus infection. We documented
that deficient TLR7 signaling contributes to significant defects
in both T and B cells, but not early control of virus replication
or DCs, demonstrating a dysfunctional adaptive immune
response. Our investigation now expands the known role of
TLR7 as an essential modulator of T and B cell responses that
are required to clear persistent virus infection.
TLR7/ mice exhibited multiple aberrations within the T cell
compartment. Soon after becoming infected with LCMV Cl 13,
these mice made significantly greater LCMV-specific T cells,
yet the infection does not resolve. We initially conjectured that
this phenomenon was the failure of T cells to migrate53, June 14, 2012 ª2012 Elsevier Inc. 649
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infected with WNV (Town et al., 2009). LCMV-specific CD8+
T cells migrated into the brain and liver similarly in both TLR7/
and TLR7+/+ mice (Figures S2A–S2C). Our data support the
likelihood that increased T cell proliferation is dependent on
the TLR7/ inflammatory environment, since adoptively trans-
ferring TLR7+/+ TCR Tg CD8+ T cells into TLR7/ mice resulted
in significantly enhanced expansion of the T cell population over
that in TLR7+/+ recipients. Although we noted modulation of
DC markers required for T cell expansion (Figures S2D–S2F),
those would not account for the great disparity in T cell numbers
between TLR7+/+ and TLR7/ mice early after LCMV infection.
In addition, when LCMV-specific T cells were cocultured with
DCs sorted from TLR7+/+ and TLR7/ mice (Figures S2I and
S2J), the proliferation profiles of both groups were similar. More-
over, the increased frequencies of infected DCs in TLR7/mice
(Figures S2G and S2H) could heighten the concentration of
MHC-peptide complexes resulting in augmented T cell prolifera-
tion. Further, a secreted factor rather than interactions with
antigen-presenting cells could promote this T cell expansion.
Although LCMV-specific T cell numbers increased, defects
in TLR7/ T cell antiviral cytokine responses were detected
after infection with both LCMV Arm and Cl 13 (Figure 2C).
Analysis of early cytokine content in the serum revealed signifi-
cantly reduced type I IFN within TLR7/ mice on day 1 after
infection (Figures S1D and S1E). Our results agree with two
studies in this issue where an early, transient decrease in serum
content of type I IFN within LCMV-Cl 13-infected TLR7/ mice
was observed when compared to TLR7+/+ mice (Macal et al.,
2012; Wang et al., 2012). Reduced type I IFN correlated with
diminished activation of T cells 1 day after infection (Macal
et al., 2012). Several groups have shown that abrogation of
type I IFN signaling within CD8+ T cells inhibited their clonal
expansion and differentiation during acute LCMV infection
(Kolumam et al., 2005; Wiesel et al., 2012). Reduced, but not
abrogated, type I IFN may contribute to diminished CD8+ T cell
antiviral potential observed within TLR7/ mice. Others have
shown that ex vivo TLR7 stimulation of TLR7+ CD8+ T cells
from HIV-infected patients induced IFN-g production, but
required accessory cells (Song et al., 2009), suggesting that
TLR7 stimulation of accessory cells likely enhanced CD8+
T cell cytokine production. Nonetheless, TLR7 signaling did
facilitate IFN-g production by CD8+ T cells. We also documented
that TLR7+/+ TCR Tg T cells adoptively transferred into TLR7/
mice 1 day prior to infection had a diminished capacity to
produce multiple antiviral cytokines when compared to similarly
treated TLR7+/+ mice (Figures 2F and 2G). In addition, the defect
in antiviral cytokine production observed in LCMV-specific
TCR Tg T cells within TLR7/ mice was equivalent to that of
endogenous TLR7/ T cells. Therefore, enhanced expansion
and the inhibited generation of polyfunctional LCMV-specific
T cells in TLR7/ mice was due to environmental factors and
was not an intrinsic property of the T cells.
CD8+ T cells are the only cells of the adaptive immune
response necessary to purge an acute LCMV Arm infection
(Matloubian et al., 1994; Tishon et al., 1995). CD8+ T cells from
LCMV Arm-infected TLR7/ mice were poor producers of
antiviral cytokines; however, the increased numbers of LCMV-
specific CD8+ T cells in these mice likely overcame the cytokine650 Cell Host & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevierdefect and contributed virus eradication by day 9 p.i. That defect
in T cell antiviral cytokine production was noted only before
the establishment of T cell exhaustion caused by LCMV Cl
13 infection. Greater than 9 days after infection, diminished
antiviral activity caused by T cell exhaustion resulted in equiva-
lent cytokine production by TLR7+/+ and TLR7/ mice (data
not shown). However, CD8+ T cells from LCMV Cl 13-infected
TLR7/ mice after day 9 postinfection had reduced granzyme
B content, a molecule involved cytotoxic lymphocyte activity,
demonstrating reduced antiviral potential (Figure 2D). These
findings correlate with a previous study in which production of
perforin, a molecule essential for CD8+ T cell lytic activity, was
enhanced in human peripheral blood mononuclear cells
(PBMCs) exposed to a TLR7 agonist (Ambach et al., 2004);
however, it is uncertain whether TLR7 stimulation of APCs
present in the isolated PBMCs promoted CD8+ T cell expression
of perforin. The cause of the diminished antiviral potential
observed in T cells from TLR7/ mice may be caused by the
antibody-deficient environment, although, as yet, there is no
definitive evidence to support this conclusion.
TLR7/ mice exhibited continuously heightened PD-1
expression, a NIR molecule necessary for LCMV Cl 13 persis-
tence (Barber et al., 2006), on LCMV-specific CD8+ T cells;
this expression exceeded that of TLR7+/+ mice starting at day
35 p.i. (Figure 3A). In addition, on day 225 after infection,
TLR7/ mice expressed high levels of multiple NIRs including
PD-1, LAG-3, 2B4, and CD160 (Figure 3B). Although, this
expression of NIRs cannot be compared to that of TLR7+/+
mice at that same time point, since the latter mice had previously
cleared LCMV Cl 13, the amount of NIR expression was compa-
rable to CD4/ mice with lifelong LCMV Cl 13 infection
(Blackburn et al., 2009). Reduced T cell antiviral potential and
increased exhaustion of immune responsiveness ultimately
contributed to LCMV Cl 13 persistence in TLR7/ mice.
Elsewhere, mice deficient in B cells failed to clear LCMV Cl
13 infection; however, those mice had dysfunctional CD4+
T cells, which are essential for CD8+ T cell-mediated clearance
of LCMV Cl 13 (Bergthaler et al., 2009; Homann et al., 1998;
Matloubian et al., 1994). Adoptive transfer of immunoglobulins,
even when concentrated 10-fold over levels found in sera of
mice that spontaneously cleared LCMV Cl 13 infection, failed
to purge virus from LCMV Cl 13 persistently infected mice
(unpublished data). Similarly, transfer of B cells from immune
mice or immune B cells and CD4+ T cells into LCMV Cl 13
persistently infected mice failed to abort that infection (unpub-
lished data), although similar transfer of immune B and CD4+
T cells into mice persistently infected with measles virus ably
cleared the infection (Tishon et al., 2006). Other studies utilizing
IL-21/ and IL-6/ mice have demonstrated that antiviral
antibody responses are associated with LCMV Cl 13 clearance,
although neutralizing antibodies from these mice have either not
been identified or found at serum neutralizing titers of less than
a 1 to 5 dilution. (Elsaesser et al., 2009; Harker et al., 2011).
Nonetheless, transfer of TLR7+/+ immune memory B cells into
TLR7+/+ mice enhanced clearance of LCMV Cl 13 (Figure 5A),
suggesting that these cells contribute to virus elimination,
although the exact mechanism of how this occurs is unclear.
Although, as documented in this report, TLR7 sufficiency was
required for the generation of anti-LCMV IgG-secreting B cellsInc.
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proliferation (Figure S3). Thus plausible, that TLR7 signaling
within B cells is required for regulation of BCL-6, Blimp-1, and
AID, genes required for the maturation of the antibody response
(McHeyzer-Williams et al., 2012).
Mice infected at birth with LCMV develop a lifelong persistent
virus infection (Oldstone, 2002). Introduction of LCMV immune
memory from TLR7+/+ mice into mice infected at birth with
LCMV induced viral clearance that required TLR7+/+ CD4+ T,
TLR7+/+ CD8+ T cells and TLR7+/+ B cells (Berger et al., 2000;
Planz et al., 1997). However, transferring TLR7+/+ immune
memory cells into TLR7/ mice failed to remove LCMV Cl 13
virus (Figure 5B), although TLR7/ DCs effectively primed and
expanded such cell populations (Figures S2I and S2J). Presum-
ably, then, an undefined cell type or nonhematopoietic cells may
also play a role in viral clearance. In addition, it is conceivable
that TLR7 signaling within LCMV Cl 13-infected cells is required
for the elimination of those cells by immune memory. Nonethe-
less, immune memory cells enhanced LCMV Cl 13 clearance
from TLR7+/+ mice, but lacked the requirements to purge
LCMV Cl 13 from TLR7/ mice.
TLR7 is essential for the development of an adaptive immune
response sufficient to eliminate persistent LCMV Cl 13 infection.
Interestingly, polymorphisms within the TLR7 gene that dimin-
ished IFN-a production after stimulation correlated directly with
the accelerated progression of HIV (Oh et al., 2009). In addition,
hepatitis C virus single-stranded RNA stimulated TLR7 signaling,
and administration of a synthetic TLR7 agonist, isatoribine,
reduced the viral burden in sera of infected patients (Horsmans
et al., 2005; Zhang et al., 2009) again relating TLR7 signaling to
the clearance of persistent virus infection in mouse models and
in humans. Understanding how TLR7 signaling contributes to
the generation of sufficient antiviral T and B cell responses to
clear acute virus infection and which molecules downstream of
TLR7 terminate persistent infection remains essential. Dissect-
ing the TLR7 pathway by using chemically tractable molecules
that can restore TLR7 signaling provides potential for the effec-
tive treatment of persistent viral infections of humans.
EXPERIMENTAL PROCEDURES
Mice and Viruses
C57Bl/6 (TLR7+/+), C57Bl/6 Ly5.1+ [B6.SJL-Ptprc(a)Pepc(b)/BoyJ], TLR7/,
C57Bl/6 Thy1.1+ DbGP33–41 TCR tg (P14) (Pircher et al., 1989), and C57Bl/6
Thy1.1+ I-AbGP66-77 TCR tg (SMARTA) (Oxenius et al., 1998) male and female
mice (6–12 weeks of age) were used. TLR7/ mice was generated on
the 129 background and bred to C57Bl/6 mice for ten generations. Histo-
compatability between TLR7/ and C57Bl/6 mice was validated by lack
of a proliferative response in a mixed lymphocyte reaction assay (data not
shown) and by the survival of adoptively transferred TLR7/ cells into
TLR7+/+ C57Bl/6 mice 60 days after transfer (Figure S4). Mice were maintained
in pathogen-free conditions, and handling conforms to the requirements of
the National Institutes of Health (NIH) and The Scripps Research Institute
animal research committee. LCMV Cl 13 and Arm strains were grown, stored,
and quantified according to published methods (Borrow et al., 1995). Serum
from blood drawn from the retro-orbital sinus, liver, lung, spleen, brains,
and kidneys were used to perform plaque assays as previously described
(Ahmed et al., 1984).
Mononuclear Cell Isolation and Adoptive Transfers
Cells were obtained by mechanical disruption of spleens, liver, and brain
through a 100 mm filter. Red blood cells were lysed by exposure of disruptedCell Htissue to a selective red blood cell lysis buffer (ammonium chloride: Tris HCl
0.02 M, NH4Cl 0.14 M). Cells per tissue were quantified with a hemocytometer
and the trypan blue exclusionmethod. For purification of splenic B and TCR Tg
T cells, cell enrichment kits were used (STEMCELL Technologies, Vancouver,
Canada). Cells were isolated to a purity of >95%. For TCR tg T cells, 1 3 104
purified cells were adoptively transferred i.v. into recipients one day prior to
infection. Immune memory B cells (2 3 107) or 3 3 107 total immune memory
splenocytes from TLR7+/+ or TLR7/ mice that were infected 45–50 days
earlier with 2 3 105 PFU of LCMV Arm and restimulated with the same dose
of LCMV Arm 3 days prior to isolation were transferred i.p. into recipients
15–20 days p.i. with LCMV Cl 13.
Cell Surface Staining
Isolated cells were stained with antibodies raised against murine antigens.
Antibodies were added to cells at dilutions of 1:100–1:400. For tetramer
staining, cells were incubated for 1 hr on ice with MHC class I tetramers for
DbGP33-41-APC and MHC II tetramer with I-A
bGP66-77-APC for 1 hr at room
temperature. Biotinylated monomers were obtained from the NIH Tetramer
Core Facility and tetramerized with streptavidin-APC (Invitrogen, Carlsbad,
CA) according to the NIH Tetramer Core Facility protocol.
Intracellular Staining and Flow Cytometry
Splenocytes were stimulated for 5 hr with 2 mg/ml of the MHC class I restricted
LCMV-GP33–41 or the MHC class II restricted LCMV-GP61-80 peptide (>99%
pure; American Peptide and The Scripps Research Institute, Center for Protein
Science, La Jolla, CA) in the presence of 4 mg/ml brefeldin A (Sigma, St Louis,
MO). Cells were fixed, permeabilized with 2% saponin, and stained intracellu-
lary with antibodies to IFN-g (XMG1.2), TNF-a (MP6-XT22), and IL-2
(JES6-5H4). Unstimulated tetramer stained (GP33-41) splenocyteswere stained
intracellularly with a 1:50 dilution of antibody against human granzyme B that
cross-reacts with mouse granzyme B (catalog number MHGB04, Invitrogen,
Carlsbad, CA). B cells were stained intracellularly with an anti-mouse IgM
antibody conjugated to Pacific Blue kindly provided by the David Nemazee
laboratory. Absolute numbers of cells were determined by multiplying the
frequency of specific cell populations by the total number of viable cells.
Bone Marrow Chimeras
Bone marrow was extracted from femurs of Ly5.1+ TLR7+/+ and Ly5.2+
TLR7/ mice, disrupted through a 100 mm mesh screen, and red blood cells
were lysed as described previously. TLR7+/+ and TLR7/ isolated bone
marrow cells (1 3 107) were adoptively transferred into lethally irradiated
(1,100 rads) Ly5.2+ TLR7+/+ mice. Bone marrow chimeric mice were main-
tained on water supplemented with antibiotics to prevent opportunistic infec-
tions for 2 months. Mice were then infected with 23 106 PFU LCMV Cl 13 and
euthanized on day 30 p.i., after which spleens were harvested to analyze
TLR7+/+ (Ly5.1+) and TLR7/ (Ly5.2+) B cell responses.
Quantification of LCMV-Specific Antibody-Secreting B Cells
and Titer of LCMV-Specific Antibody
For determination of the number of LCMV-specific antibody secreting B cells,
5 3 106 PFU of LCMV Arm or 100 ml PBS containing 10–15 mg of BHK cell
lysates infected with LCMV was plated per well in a 96-well nitrocellulose
bottom plate overnight (o/n) at 4C. Plates were blocked with 5% FBS for
1 hr at room temperature (rt); 1 3 106 sorted splenic B cells were plated per
well and 3-fold serial dilutions were performed eight times. The plate was
incubated at 37C at 5% CO2 for 5 hr. One hundred microliters of 2 mg/ml of
biotinylated anti-mouse IgG was added to the wells and incubated o/n at
4C. One hundred microliters of 5 mg/ml of horse radish peroxidase (HRP)-
conjugated avidin was added to the wells for 1 hr at rt followed by incubation
with AEC chromogen substrate until red dots appeared. The reaction was
stopped by rinsing of the plate in tap water, and dots were counted manually
with a dissection microscope. For determination of anti-LCMV antibody titer,
ELISA clear-bottom plates were coatedwith antigen and blocked as described
above. Ten-fold serial dilutions of serum isolated from mice were incubated in
the wells o/n at 4C. One hundred microliters of 2 mg/ml of biotinylated
anti-mouse IgGwas added to thewells and incubated o/n at 4C.One hundred
microliters of 5 mg/ml of HRP-conjugated avidin was added to the wells for 1 hr
at rt followed by 100 ml of substrate reagent (R&D Systems, Minneapolis, MN)ost & Microbe 11, 643–653, June 14, 2012 ª2012 Elsevier Inc. 651
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was read at 450 nm.
Statistics
ANOVA or an unpaired two-tailed Student’s t test was calculated with Excel
or GraphPad Prism 5, when appropriate, to determine significance, which
was set at 5%.
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